New diagnostic panel helps detect canine lymphoma early

Staff ReporterJanuary 26, 202543 min
A cute brown dog sleeping peacefully on the blue covers of a sofa

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, has announced the launch of IDEXX Cancer Dx, a first-of-its-kind diagnostic panel for early detection of lymphoma in dogs. According to a press release from the company, IDEXX Cancer Dx is an affordable and accessible blood test that can be added to panels for sick pets and integrated into annual wellness screenings for as low as $15, or about Rs1,300, giving veterinarians in the USA actionable results within 2–3 days. Veterinarians in Canada will have access to IDEXX Cancer Dx results within 2–4 days. The company has not said when the test will become available for veterinarians elsewhere in the world.

Cancer remains a leading cause of death in dogs, with one in four dogs in the USA expected to be diagnosed with the disease in their lifetime, according to the Veterinary Cancer Society. Lymphoma, one of the more common cancers in dogs, accounts for nearly a quarter of new cancer diagnoses, according to the sixth edition of Withrow and MacEwen’s Small Animal Clinical Oncology, published by Saunders.

Also Read: Groundbreaking study to use AI to help cancer detection in dogs

Treatment for canine lymphoma may help to extend the affected animal’s life span and improve its quality of life, highlighting the critical need for early detection and intervention to improve outcomes. A recent survey by IDEXX Laboratories in May last year suggested that 73% of pet owners were keen to have a cancer screening test for their pet, signalling a strong demand for proactive, wellness-driven care.

Early data from testing at IDEXX reference laboratories in North America between November 1 and December 6 show IDEXX Cancer Dx testing can detect lymphoma before clinical signs are present, supporting its utility in routine preventive care for at-risk dogs, the company said in its release.

Also Read: Largest preventive canine cancer vaccine trial ends

“Building on over 40 years of IDEXX’s leadership in veterinary research and technology development, IDEXX Cancer Dx is our latest groundbreaking solution to deliver unmatched diagnostic insights,” said Jay Mazelsky, president and chief executive officer. “As leaders in key cancer diagnostic categories, like pathology and imaging, we continue to innovate technologies that can redefine how veterinarians approach cancer detection and monitoring in pets. We are proud to be at the forefront of early cancer detection in dogs and look forward to expanding IDEXX Cancer Dx to cover other cancer types.”

According to the press release, the IDEXX Cancer Dx panel features:

  • Accuracy: High sensitivity and specificity yield results that can be used with confidence for both sick dogs and in routine preventive care for at-risk dogs.
  • Simplicity: Designed to fit existing veterinary workflows, clinicians can add IDEXX Cancer Dx to existing diagnostic wellness panels, using a single blood sample.
  • Personalized guidance and comprehensive support: Every IDEXX Cancer Dx result comes with access to IDEXX medical consultants, including board-certified oncologists and internists. Pet-owner education materials and resources to support client communications are also provided.
  • Actionable next steps: IDEXX Cancer Dx with lymphoma delivers qualitative results for lymphoma, and B-cell and T-cell phenotype classification will be provided with positive results as available at no additional cost.
  • Deeper insights: IDEXX Preventive Care, a comprehensive portfolio of products and services supporting veterinarians with preventive care, will now include IDEXX Cancer Dx testing, unlocking additional insights for at-risk dogs.

“IDEXX Cancer Dx is a powerful innovation in oncology diagnostics,” said Timothy Fan, DVM, PhD, DACVIM (Oncology, Small Animal Internal Medicine). “At an affordable price point, this test increases access to cancer diagnoses and care, and it enables veterinarians the opportunity to intervene sooner and improve the quality of life for canine cancer patients.”

Also Read: Petco Love, Blue Buffalo promise $100,000 for cancer research

With IDEXX Cancer Dx testing, general veterinary practitioners can now provide a clinical diagnosis of lymphoma earlier than traditional diagnostics, as per the company’s data. Its affordability and ease of integration make it an essential tool for practices committed to proactive cancer management.

IDEXX Cancer Dx with canine lymphoma will be available at the IDEXX reference laboratories in the USA and Canada in late March. To know more, visit the IDEXX Cancer Dx testing web page.

IDEXX Laboratories, a member of the New York Stock Exchange’s benchmark S&P 500 Index, is headquartered in Westbrook, Maine, and employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories.

SOURCE: PR Newswire

Caution: Information in news reports, press releases, or articles on TheSnout.in is not intended to serve as a medical opinion or advice. Do not attempt to treat yourself or your pets without consulting the appropriate medical professional.

Staff Reporter

Leave a Reply

Your email address will not be published. Required fields are marked *